Study19Study16NCT00330681NCT01492686amyotrophic lateral sclerosisedaravoneALSALS-Functional-Rating-Scale-RevisedPharmaceutical Benefits Scheme
…cluded data from two pivotal trials, Study16 ( NCT00330681) and Study19 (NCT01492686), where patients with ALS were randomised to recei…